# Christopher Hourigan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5358178/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 118 papers | 6,076 citations | 172207 29 h-index | 82410 72 g-index |
| 126 all docs | 126 docs citations | 126 times ranked | 7755 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Functional genomic landscape of acute myeloid leukaemia. Nature, 2018, 562, 526-531. | 13.7 | 907 |
| 2 | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291. | 0.6 | 796 |
| 3 | Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638. | 13.9 | 580 |
| 4 | 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767. | 0.6 | 305 |
| 5 | Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. Journal of Clinical Oncology, 2020, 38, 1273-1283. | 0.8 | 281 |
| 6 | The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481. | 2.0 | 229 |
| 7 | Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1890. | 3.4 | 207 |
| 8 | Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica, 2017, 102, 865-873. | 1.7 | 206 |
| 9 | Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 2017, 31, 1482-1490. | 3.3 | 197 |
| 10 | Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology, 2013, 10, 460-471. | 12.5 | 168 |
| 11 | The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor Î¶ Chain. Journal of Biological Chemistry, 2001, 276, 32786-32792. | 1.6 | 138 |
| 12 | Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight, 2018, 3, . | 2.3 | 135 |
| 13 | American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Advances, 2020, 4, 3528-3549. | 2.5 | 113 |
| 14 | Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine, 2015, 4, 665-695. | 1.0 | 98 |
| 15 | NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2018, 24, 1019-1029. | 3.2 | 87 |
| 16 | Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Reviews, 2017, 31, 185-192. | 2.8 | 83 |
| 17 | The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation. Genes and Development, 2019, 33, 482-497. | 2.7 | 74 |
| 18 | A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using Î±3 Domain Mutants of MHC Class I/Peptide Complex. Immunity, 2001, 14, 591-602. | 6.6 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The clinical and financial burden of pre-emptive management ofÂcytomegalovirus disease after allogeneic stem cell transplantationâ€"implications for preventative treatment approaches. Cytotherapy, 2014, 16, 927-933. | 0.3 | 56 |
| 20 | Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromesâ€"Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 483.e1-483.e6. | 0.6 | 52 |
| 21 | Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia, 2021, 35, 1529-1538. | 3.3 | 48 |
| 22 | Immunological effects of hypomethylating agents. Expert Review of Hematology, 2017, 10, 745-752. | 1.0 | 46 |
| 23 | Heterogeneity in refractory acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10494-10503. | 3.3 | 40 |
| 24 | Pathogenic TERT promoter variants in telomere diseases. Genetics in Medicine, 2019, 21, 1594-1602. | 1.1 | 37 |
| 25 | Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 154-163. | 2.0 | 36 |
| 26 | Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. Journal of Translational Medicine, 2017, 15, 155. | 1.8 | 35 |
| 27 | Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357. | 2.5 | 35 |
| 28 | Nextâ€generation sequencing for measurable residual disease detection in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 77-85. | 1.2 | 34 |
| 29 | Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392. | | 34 |
| 30 | Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia, 2014, 28, 1167-1170. | 3.3 | 33 |
| 31 | A multigene array for measurable residual disease detection in AML patients undergoing SCT. Bone Marrow Transplantation, 2015, 50, 642-651. | 1.3 | 33 |
| 32 | Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. Haematologica, 2019, 104, 297-304. | 1.7 | 33 |
| 33 | MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leukemia Research, 2019, 76, 70-75. | 0.4 | 33 |
| 34 | Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 184-192. | 1.8 | 32 |
| 35 | Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 843-850. | 1.3 | 32 |
| 36 | Identification of novel microRNA signatures linked to acquired aplastic anemia. Haematologica, 2015, 100, 1534-1545. | 1.7 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. Blood, 2020, 135, 1185-1188. | 0.6 | 29 |
| 38 | Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. Blood Advances, 2020, 4, 367-379. | 2.5 | 29 |
| 39 | MRD evaluation of AML in clinical practice: are we there yet?. Hematology American Society of Hematology Education Program, 2019, 2019, 557-569. | 0.9 | 27 |
| 40 | The molecular basis of coeliac disease. Clinical and Experimental Medicine, 2006, 6, 53-59. | 1.9 | 26 |
| 41 | Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Experimental Hematology, 2014, 42, 83-89. | 0.2 | 26 |
| 42 | When the Minimal Becomes Measurable. Journal of Clinical Oncology, 2016, 34, 2557-2558. | 0.8 | 26 |
| 43 | Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2017, 6, 87. | 1.0 | 24 |
| 44 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery, 2019, 84, 945-953. | 0.6 | 24 |
| 45 | Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis. Blood Cancer Discovery, 2021, 2, 319-325. | 2.6 | 24 |
| 46 | Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1974-1982. | 2.0 | 23 |
| 47 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2018, 132, 1437-1437. | 0.6 | 22 |
| 48 | Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer Journal, 2013, 3, e145-e145. | 2.8 | 21 |
| 49 | The Prognostic Significance of Measurable (â€œMinimalâ€) Residual Disease in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 547-556. | 1.2 | 19 |
| 50 | Evaluation of Current Cancer Immunotherapy. Cancer Journal (Sudbury, Mass ), 2011, 17, 309-324. | 1.0 | 18 |
| 51 | Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 911-917. | 1.3 | 18 |
| 52 | BarrettÊ¼s, blood groups and progression to oesophageal cancer. European Journal of Gastroenterology and Hepatology, 2011, 23, 801-806. | 0.8 | 16 |
| 53 | Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. Frontiers in Oncology, 2018, 8, 669. | 1.3 | 15 |
| 54 | Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9. | 0.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12. | 0.6 | 15 |
| 56 | Adult Acute Myeloid Leukemia Long-Term Survivors. Journal of Leukemia (Los Angeles, Calif ), 2014, 02, . | 0.1 | 14 |
| 57 | Precision medicine for acute myeloid leukemia. Expert Review of Hematology, 2016, 9, 1-3. | 1.0 | 14 |
| 58 | Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. Current Drug Targets, 2017, 18, 296-303. | 1.0 | 14 |
| 59 | Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2014, 20, 209-213. | 2.0 | 13 |
| 60 | Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precision Oncology, 2021, 5, 265-274. | 1.5 | 13 |
| 61 | An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077. | 1.3 | 13 |
| 62 | Personalized Therapy for Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1336-1338. | 7.7 | 12 |
| 63 | Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation. Leukemia Research Reports, 2019, 12, 100176. | 0.2 | 11 |
| 64 | The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: Steric hindrance influences TCR allo-recognition. European Journal of Immunology, 2006, 36, 3288-3293. | 1.6 | 10 |
| 65 | Detectable mutations precede late myeloid neoplasia in aplastic anemia. Haematologica, 2021, 106, 647-650. | 1.7 | 10 |
| 66 | Development of therapeutic agents for older patients with acute myelogenous leukemia. Current Opinion in Investigational Drugs, 2010, 11, 669-77. | 2.3 | 10 |
| 67 | Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors. Bone Marrow Transplantation, 2014, 49, 451-452. | 1.3 | 9 |
| 68 | Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection. Leukemia Research Reports, 2017, 8, 4-6. | 0.2 | 9 |
| 69 | Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. Therapeutic Advances in Hematology, 2018, 9, 109-121. | 1.1 | 9 |
| 70 | Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and CoronaryAPlaque. Journal of Investigative Dermatology, 2020, 140, 912-915.e1. | 0.3 | 9 |
| 71 | Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances, 2021, 5, 1757-1759. | 2.5 | 9 |
| 72 | A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. Journal of Palliative Medicine, 2017, 20, 1267-1273. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A Prospective Pilot Study to Evaluate Molecular Changes in the Hematopoietic System after Receipt of Chemotherapy or Radiotherapy and Its Clinical Implications Among Racially Diverse Breast Cancer Survivors: Breast Survivorchip Study. Blood, 2020, 136, 34-35. | 0.6 | 8 |
| 74 | New considerations in the design of clinical trials for the treatment of acute leukemia. Clinical Investigation, 2011, 1, 509-517. | 0.0 | 7 |
| 75 | Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplantation, 2015, 50, 189-196. | 1.3 | 7 |
| 76 | Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects. American Journal of Hematology, 2020, 95, 662-671. | 2.0 | 7 |
| 77 | CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Supportive Care in Cancer, 2016, 24, 815-822. | 1.0 | 6 |
| 78 | Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass ), 2022, 28, 73-77. | 1.0 | 6 |
| 79 | Next Generation MRD. Biology of Blood and Marrow Transplantation, 2014, 20, 1259-1260. | 2.0 | 5 |
| 80 | Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Advances, 2019, 3, 980-983. | 2.5 | 5 |
| 81 | Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847. | 2.5 | 5 |
| 82 | Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. Blood, 2013, 122, 3885-3885. | 0.6 | 5 |
| 83 | Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults. Blood, 2016, 128, 1644-1644. | 0.6 | 5 |
| 84 | Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Hematology International, 2020, 2, 27. | 0.7 | 5 |
| 85 | Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. Leukemia and Lymphoma, 2013, 54, 2563-2564. | 0.6 | 4 |
| 86 | Refining AML outcome prediction. Leukemia, 2019, 33, 283-284. | 3.3 | 4 |
| 87 | Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S8-S17. | 2.0 | 3 |
| 88 | Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 1138-1140. | 1.3 | 3 |
| 89 | Leukaemia risk associated with low-dose radiation. Lancet Haematology,the, 2018, 5, e324-e325. | 2.2 | 3 |
| 90 | Utility of plasma cell-free DNA for <i>de novo</i> detection and quantification of clonal hematopoiesis. Haematologica, 2022, 107, 1815-1826. | 1.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia. Clinical Hematology International, 2020, 2, 125. | 0.7 | 3 |
| 92 | Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults. Blood, 2020, 136, 41-42. | 0.6 | 3 |
| 93 | Acute Myeloid Leukemia: Introduction. Seminars in Hematology, 2015, 52, 149. | 1.8 | 2 |
| 94 | Editorial (Thematic Issue: Targets for Immunotherapy in Acute Leukemia). Current Drug Targets, 2017, 18, 256-256. | 1.0 | 2 |
| 95 | Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. Cancer Research, 2021, 81, CT138-CT138. | 0.4 | 2 |
| 96 | Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome. Blood, 2013, 122, 593-593. | 0.6 | 2 |
| 97 | Registering organ donor preferences - a third way?. British Journal of General Practice, 2005, 55, 805. | 0.7 | 2 |
| 98 | Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia. Leukemia Research Reports, 2014, 3, 46-48. | 0.2 | 1 |
| 99 | Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. Cancer Discovery, 2016, 6, 1087-1089. | 7.7 | 1 |
| 100 | Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PLoS ONE, 2021, 16, e0249087. | 1.1 | 1 |
| 101 | Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. Journal of Clinical Oncology, 2021, 39, 2413-2415. | 0.8 | 1 |
| 102 | High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function. Blood, 2013, 122, 2567-2567. | 0.6 | 1 |
| 103 | Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia. Blood, 2015, 126, 3616-3616. | 0.6 | 1 |
| 104 | Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia. Blood, 2021, 138, 4444-4444. | 0.6 | 1 |
| 105 | Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis. Blood, 2021, 138, 414-414. | 0.6 | 1 |
| 106 | Single-Cell Transcriptomic and Proteomic Analysis of Acute Myeloid Leukemia (AML) Patients with Abnormalities on Chromosome 7. Blood, 2021, 138, 1289-1289. | 0.6 | 1 |
| 107 | Post-Transplant Pulmonary Function Abnormalities Nadir At Five Years and Then Fully Normalize by the Second Decade in Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2013, 19, S151. | 2.0 | 0 |
| 108 | Haplo, we have a problem. Blood, 2017, 130, 1180-1180. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Are medical schools fit for graduates?. BMJ: British Medical Journal, 2005, 331, 1084.1. | 2.4 | 0 |
| 110 | CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 3898-3898. | 0.6 | 0 |
| 111 | Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2550-2550. | 0.6 | 0 |
| 112 | Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile. Blood, 2015, 126, 3427-3427. | 0.6 | 0 |
| 113 | Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct. Blood, 2015, 126, 3212-3212. | 0.6 | 0 |
| 114 | A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia. Blood, 2019, 134, 2709-2709. | 0.6 | 0 |
| 115 | Highly Multiplexed Cell Surface Immunophenotyping with Genotyping and Concurrent Transcriptomic Analysis of NPM1 mutated Acute Myeloid Leukemia. Blood, 2021, 138, 1288-1288. | 0.6 | 0 |
| 116 | Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. Blood, 2021, 138, 1846-1846. | 0.6 | 0 |
| 117 | Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. Blood, 2020, 136, 16-17. | 0.6 | 0 |
| 118 | Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL. Blood, 2020, 136, 42-44. | 0.6 | 0 |